GlassScriptPhysician profile
Nassim H Nabbout
NPI 1528029147
$28,101.79
in general payments reported to CMS, 2019-2025
91 companies · $3,372 in 2025
The $3,372 reported for 2025 was more than what 76% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,842 · 2020: $4,673 · 2021: $5,533 · 2022: $3,828 · 2023: $3,543 · 2024: $3,311 · 2025: $3,372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,012.57 |
| Education | $213.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,383.42 | 2019-2025 | |
| Pfizer INC. | $1,765.11 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,727.65 | 2019-2025 | Opdivo, Opdualag |
| Rigel Pharmaceuticals, INC. | $1,077.67 | 2019-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Merck Sharp & Dohme LLC | $1,068.04 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals LP | $1,055.57 | 2019-2025 | Imfinzi, Enhertu, Calquence |
| Genentech USA, INC. | $1,021.27 | 2019-2025 | Lunsumio, Polivy, Columvi |
| Amgen INC. | $1,013.84 | 2019-2023 | Kyprolis, Blincyto, Xgeva |
| Dova Pharmaceuticals | $1,005.06 | 2020 | |
| Seagen INC. | $915.13 | 2019-2023 | Padcev, Tukysa, Adcetris |
| Karyopharm Therapeutics INC. | $860.26 | 2020-2022 | |
| Abbvie INC. | $837.28 | 2019-2025 | |
| Celgene Corporation | $776.01 | 2021-2025 | Reblozyl, Pomalyst, Opdualag |
| Genzyme Corporation | $699.25 | 2019-2025 | |
| Emd Serono, INC. | $644.84 | 2019-2025 | Bavencio |
Show all 91 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $586.19 | 2019-2025 | Enhertu, Vanflyta, Datroway |
| Janssen Biotech, INC. | $532.45 | 2019-2025 | Erleada, Tecvayli, Talvey |
| Verity Pharmaceuticals INC. | $500.00 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $465.86 | 2019-2025 | Iclusig, Fruzaqla, Ninlaro |
| Gilead Sciences, INC. | $447.44 | 2021-2025 | Trodelvy |
| Array Biopharma INC | $442.95 | 2019-2025 | Braftovi, Mektovi, Lorbrena |
| Astellas Pharma US INC | $438.84 | 2019-2025 | Xospata, Vyloy, Xtandi |
| Glaxosmithkline, LLC. | $437.08 | 2020-2025 | Ojjaara, Zejula, Jemperli |
| Lilly USA, LLC | $390.53 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Eisai INC. | $376.29 | 2019-2025 | |
| Aveo Pharmaceuticals, INC. | $368.43 | 2021-2025 | Fotivda |
| Exelixis INC. | $359.67 | 2019-2025 | Cabometyx |
| Incyte Corporation | $302.19 | 2019-2025 | Monjuvi, Jakafi, Zynyz |
| Epizyme, INC. | $296.11 | 2020-2022 | |
| Puma Biotechnology, INC. | $278.88 | 2019-2022 | |
| Kite Pharma, INC. | $265.44 | 2020-2025 | Yescarta |
| Regeneron Healthcare Solutions, INC. | $230.60 | 2020-2025 | Libtayo |
| Pharmacyclics LLC, An Abbvie Company | $212.39 | 2020-2023 | Epkinly, Imbruvica |
| Bayer Healthcare Pharmaceuticals INC. | $199.72 | 2019-2024 | |
| Deciphera Pharmaceuticals INC. | $183.86 | 2021-2024 | Qinlock |
| Blueprint Medicines Corporation | $179.43 | 2020-2024 | Ayvakit |
| Clovis Oncology, INC. | $177.41 | 2019-2022 | |
| Beigene USA, INC. | $164.94 | 2020-2022 | |
| Sobi, INC | $164.29 | 2022-2025 | |
| Tersera Therapeutics LLC | $157.62 | 2021-2025 | Xermelo, Zoladex, Quzyttir |
| Servier Pharmaceuticals LLC | $150.31 | 2022-2025 | |
| Apellis Pharmaceuticals, INC. | $136.58 | 2023-2025 | Empaveli |
| Aurobindo Pharma USA, INC. | $122.19 | 2020 | |
| Intuitive Surgical, INC. | $118.03 | 2025 | |
| Pharmaessentia USA Corporation | $115.50 | 2022-2024 | Besremi |
| Jazz Pharmaceuticals INC. | $113.84 | 2019-2025 | |
| Stemline Therapeutics INC. | $110.49 | 2023-2025 | Orserdu |
| Acrotech Biopharma INC. | $110.20 | 2021-2025 | Beleodaq |
| Sun Pharmaceutical Industries INC. | $107.58 | 2019-2021 | |
| Springworks Therapeutics, INC. | $107.40 | 2024-2025 | Ogsiveo |
| Taiho Oncology, INC. | $107.28 | 2019-2024 | |
| Agios Pharmaceuticals, INC. | $107.22 | 2020-2024 | Pyrukynd |
| Mirati Therapeutics, INC. | $99.14 | 2023-2024 | Krazati |
| Spectrum Pharmaceuticals INC. | $95.95 | 2023-2025 | Rolvedon |
| Foundation Medicine, INC. | $90.68 | 2019-2021 | |
| Ipsen Biopharmaceuticals, INC | $81.88 | 2019-2024 | Onivyde, Tazverik |
| Cti Biopharma Corp. | $77.04 | 2022-2023 | Vonjo |
| Alexion Pharmaceuticals, INC. | $71.66 | 2021-2023 | Ultomiris |
| Avyxa Pharma, LLC | $67.10 | 2025 | |
| G1 Therapeutics, INC. | $64.40 | 2022-2023 | Cosela |
| Pharmacosmos Therapeutics INC. | $60.82 | 2024-2025 | Monoferric, Cosela |
| Iovance Biotherapeutics, INC. | $57.77 | 2024-2025 | Amtagvi |
| Azurity Pharmaceuticals, INC. | $57.71 | 2025 | Danziten |
| Octapharma USA, INC. | $54.61 | 2023-2025 | Octagam Immune Globulin (Human) |
| Genmab U.S., INC. | $52.50 | 2024-2025 | Epkinly, Tivdak |
| Sumitomo Pharma America, INC. | $49.81 | 2023-2025 | Orgovyx |
| Adaptive Biotechnologies Corporation | $46.21 | 2024 | Clonoseq |
| Geron Corporation | $46.15 | 2025 | Rytelo |
| Kyowa Kirin, INC. | $44.44 | 2019-2024 | Poteligeo |
| Tg Therapeutics, INC. | $42.79 | 2022 | |
| Blue Earth Diagnostics | $41.94 | 2021-2025 | Posluma |
| Bio Products Laboratory USA, INC. | $40.01 | 2019 | |
| Myovant Sciences INC. | $39.86 | 2022 | |
| Syndax Pharmaceuticals, INC. | $38.49 | 2025 | |
| Accord Healthcare, INC. | $37.79 | 2024-2025 | |
| Lexicon Pharmaceuticals, INC. | $35.52 | 2020 | |
| Tolmar Pharmaceuticals, INC. | $29.57 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.24 | 2025 | |
| Amag Pharmaceuticals, INC. | $25.24 | 2019-2020 | |
| Acceleron Pharma, INC. | $24.31 | 2021 | |
| Adc Therapeutics America, INC. | $23.57 | 2024 | |
| Alnylam Pharmaceuticals INC. | $20.28 | 2020 | |
| Morphosys, US INC. | $19.98 | 2022 | |
| Tesaro, INC. | $18.63 | 2019 | |
| Heron Therapeutics, INC. | $15.40 | 2019 | |
| Mylan Institutional INC. | $15.37 | 2022 | |
| Recordati_rare_diseases_inc. | $15.32 | 2025 | Sylvant |
| Myriad Genetic Laboratories, INC. | $15.29 | 2023 | Myrisk |
| Csl Behring | $14.02 | 2020 | |
| Legend Biotech USA INC. | $13.99 | 2025 | Carvykti |
| Immunomedics, INC. | $11.68 | 2020 |
Drugs and devices associated with these payments
Opdivo $500Ibrance $419Enhertu $341Epkinly $330Keytruda $323Imbruvica $297Reblozyl $288Venclexta $270Tukysa $243Braftovi $218Xtandi $202Elrexfio $201Mektovi $200Fabhalta $199Bavencio $196Fotivda $187Cabometyx $186Lorbrena $182Adcetris $176Verzenio $176Bosulif $172Talzenna $165Lenvima $164Kisqali $161Lynparza $156Tavalisse $156Rezlidhia $156Pomalyst $146Orgovyx $141Padcev $141Empaveli $137Opdualag $134Doptelet $131Trodelvy $125Iclusig $121Welireg $120Da Vinci Surgical System $118Jevtana $116Libtayo $115Comirnaty $112Ojjaara $111Orserdu $110Ogsiveo $107Lunsumio $107Paxlovid $104Krazati $99.14Inlyta $96.37Rolvedon $95.95Besremi $94.19Sarclisa $90.33Imfinzi $90.30Polivy $85.37Kyprolis $79.54Xalkori $78.34Elahere $76.40Xospata $72.81Cosela $70.92Zepzelca $69.63Enjaymo $69.50Jemperli $64.80Zejula $64.80Columvi $62.81Blincyto $61.14Qinlock $61.00Scemblix $58.80Amtagvi $57.77Danziten $57.71Monjuvi $57.49Xermelo $57.02Tecentriq $56.86Octagam Immune Globulin (Human) $54.61Gavreto $50.76Cablivi $49.67Vonjo $49.42Piqray $48.49Clonoseq $46.21Rytelo $46.15Docivyx $45.64Frindovyx $43.96Posfrea $43.96Axtle $43.96Erleada $41.67Itovebi $41.65Monoferric $40.70Voranigo $40.52Yescarta $40.11Calquence $39.55Beleodaq $38.31Eliquis $38.27Camcevi $37.79Idhifa $37.53Zoladex $37.52Ultomiris $36.30Ayvakit $36.29Tibsovo $36.18Vyloy $35.61Phesgo $35.06Pluvicto $31.21Besponsa $31.08Jakafi $30.77
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nassim Nabbout listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.